Literature DB >> 29973083

Imaging artifacts of Onyx and PHIL on conventional CT, cone-beam CT and MRI in an animal model.

Dominik F Vollherbst1,2, Ruth Otto1, Thuy Do2, Hans U Kauczor2, Martin Bendszus1, Christof M Sommer2,3, Markus A Möhlenbruch1.   

Abstract

BACKGROUND AND
PURPOSE: A frequently reported drawback of ethylene vinyl alcohol copolymer-based liquid embolic agents is the production of artifacts in diagnostic imaging. New embolic agents, such as Precipitating hydrophobic injectable liquid (PHIL; MicroVention, Tustin, CA, USA), are supposed to induce significantly fewer artifacts. The purpose of this study is to assess the degree of artifacts induced by the liquid embolic agents Onyx (Medtronic Neurovascular, Irvine, CA, USA) and PHIL in conventional computed tomography (CT), cone-beam CT and magnetic resonance imaging (MRI) in an experimental in vivo model.
MATERIALS AND METHODS: In 10 pigs the rete mirabile was embolized with Onyx ( n = 5) or PHIL ( n = 5). After embolization, conventional CT, cone-beam CT and MRI were performed. The degree of artifacts was graded qualitatively (five-point scale; for CT and MRI) and quantitatively (HUs of well-defined regions of interest (ROIs); for CT only).
RESULTS: Artifacts were significantly more severe for Onyx both in the qualitative (e.g. conventional CT: 2 versus 5 (medians); p = 0.008) and in the quantitative image analysis (e.g. cone-beam CT: standard deviation of a ROI near to the embolic agent cast, 94 HU versus 38 HU (medians); p = 0.008). Neither Onyx nor PHIL produced any apparent artifacts in MRI.
CONCLUSION: PHIL produces fewer artifacts than Onyx in conventional CT and cone-beam CT in an experimental in vivo model.

Entities:  

Keywords:  Arteriovenous malformation; artifacts; embolization; liquid embolic agents

Mesh:

Substances:

Year:  2018        PMID: 29973083      PMCID: PMC6259339          DOI: 10.1177/1591019918782692

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  26 in total

Review 1.  Clinical practice. Arteriovenous malformations of the brain.

Authors:  Robert M Friedlander
Journal:  N Engl J Med       Date:  2007-06-28       Impact factor: 91.245

2.  Endovascular treatment of brain arteriovenous malformations using a liquid embolic agent: results of a prospective, multicentre study (BRAVO).

Authors:  L Pierot; C Cognard; D Herbreteau; H Fransen; W J van Rooij; E Boccardi; A Beltramello; N Sourour; K Kupcs; A Biondi; A Bonafé; W Reith; A Casasco
Journal:  Eur Radiol       Date:  2013-05-08       Impact factor: 5.315

3.  Experimental study of temperature-sensitive chitosan/β-glycerophosphate embolic material in embolizing the basicranial rete mirabile in swines.

Authors:  Xianbin Ning; Changfu Zhao; Jinfeng Pang; Zhaoyi Ding; Yubo Wang; Kan Xu; Hao Chen; Bingwei Li; Q I Luo
Journal:  Exp Ther Med       Date:  2015-05-07       Impact factor: 2.447

4.  Electrochemical Effects after Transarterial Chemoembolization in Combination with Percutaneous Irreversible Electroporation: Observations in an Acute Porcine Liver Model.

Authors:  Dominik Vollherbst; Robert C Bertheau; Stefan Fritz; Carolin Mogler; Hans-Ulrich Kauczor; Eduard Ryschich; Boris A Radeleff; Philippe L Pereira; Christof M Sommer
Journal:  J Vasc Interv Radiol       Date:  2016-04-18       Impact factor: 3.464

5.  Evaluation of a novel liquid embolic agent (precipitating hydrophobic injectable liquid (PHIL)) in an animal endovascular embolization model.

Authors:  Christof M Sommer; Markus A Möhlenbruch; Dominik F Vollherbst; Ruth Otto; Andreas von Deimling; Johannes Pfaff; Christian Ulfert; Hans U Kauczor; Martin Bendszus
Journal:  J Neurointerv Surg       Date:  2017-07-08       Impact factor: 5.836

6.  Dosimetric measurements of Onyx embolization material for stereotactic radiosurgery.

Authors:  Donald A Roberts; James M Balter; Neeraj Chaudhary; Joseph J Gemmete; Aditya S Pandey
Journal:  Med Phys       Date:  2012-11       Impact factor: 4.071

7.  Preclinical study on an animal model of a new non-adhesive cyanoacrylate (Purefill®) for arterial embolization.

Authors:  J Izaaryene; M Saeed Kilani; P-H Rolland; J-Y Gaubert; A Jacquier; J-M Bartoli; V Vidal
Journal:  Diagn Interv Imaging       Date:  2016-07-27       Impact factor: 4.026

8.  Diagnosis and treatment of vascular malformations of the brain.

Authors:  Bradley A Gross; Rose Du
Journal:  Curr Treat Options Neurol       Date:  2014-01       Impact factor: 3.598

9.  Artifacts in CT: recognition and avoidance.

Authors:  Julia F Barrett; Nicholas Keat
Journal:  Radiographics       Date:  2004 Nov-Dec       Impact factor: 5.333

10.  Time-of-flight magnetic resonance angiography imaging of a residual arteriovenous malformation nidus after Onyx embolization for stereotactic radiosurgery planning. Technical note.

Authors:  David N Loy; Keith M Rich; Joseph Simpson; Ian Dorward; Lakshmi Santanam; Colin P Derdeyn
Journal:  Neurosurg Focus       Date:  2009-05       Impact factor: 4.047

View more
  10 in total

1.  Endovascular treatment of cerebral dural arteriovenous fistulas with SQUID 12.

Authors:  Emilio Lozupone; Sandra Bracco; Pietro Trombatore; Luca Milonia; Francesco D'Argento; Andrea Alexandre; Iacopo Valente; Vittorio Semeraro; Samuele Cioni; Alessandro Pedicelli
Journal:  Interv Neuroradiol       Date:  2020-08-25       Impact factor: 1.610

2.  Imaging Artifacts of Liquid Embolic Agents on Conventional CT in an Experimental in Vitro Model.

Authors:  N Schmitt; R O Floca; D Paech; R A El Shafie; F Seker; M Bendszus; M A Möhlenbruch; D F Vollherbst
Journal:  AJNR Am J Neuroradiol       Date:  2020-11-19       Impact factor: 3.825

3.  Iterative metal artifact reduction in aortic CTA after Onyx®-embolization.

Authors:  Leena Lehti; Marcus Söderberg; Helena Mellander; Johan Wassélius
Journal:  Eur J Radiol Open       Date:  2020-09-04

4.  Liquid Embolic Agents in Spectral X-Ray Photon-Counting Computed Tomography using Tantalum K-Edge Imaging.

Authors:  Isabelle Riederer; Daniel Bar-Ness; Melanie A Kimm; Salim Si-Mohamed; Peter B Noël; Ernst J Rummeny; Philippe Douek; Daniela Pfeiffer
Journal:  Sci Rep       Date:  2019-03-27       Impact factor: 4.379

5.  The impact of software-based metal artifact reduction on the liquid embolic agent Onyx in cone-beam CT: a systematic in vitro and in vivo study.

Authors:  Niclas Schmitt; Charlotte S Weyland; Lena Wucherpfennig; Christof M Sommer; Martin Bendszus; Markus A Möhlenbruch; Dominik F Vollherbst
Journal:  J Neurointerv Surg       Date:  2021-08-25       Impact factor: 8.572

6.  Iterative Metal Artifact Reduction (iMAR) of the Non-adhesive Liquid Embolic Agent Onyx in Computed Tomography : An Experimental Study.

Authors:  Niclas Schmitt; Charlotte S Weyland; Lena Wucherpfennig; Christian Herweh; Martin Bendszus; Markus A Möhlenbruch; Dominik F Vollherbst
Journal:  Clin Neuroradiol       Date:  2021-10-13       Impact factor: 3.156

7.  Feasibility of Metal Artifact Reduction on CT Angiography for Planning Direct Surgery of Tentorial dAVF after Onyx Embolization.

Authors:  Kanji Nakagawa; Shingo Toyota; Takeshi Shimizu; Tomoaki Murakami; Takuyu Taki
Journal:  Asian J Neurosurg       Date:  2022-08-25

8.  Cytokines CCL2 and CXCL1 may be potential novel predictors of early bone loss.

Authors:  Yaqian Hu; Long Wang; Zhuojie Zhao; Weiguang Lu; Jing Fan; Bo Gao; Zhuojing Luo; Qiang Jie; Xiaojuan Shi; Liu Yang
Journal:  Mol Med Rep       Date:  2020-09-28       Impact factor: 2.952

9.  Imaging Artifacts of Nonadhesive Liquid Embolic Agents in Conventional and Cone-beam CT in a Novel in Vitro AVM Model.

Authors:  Niclas Schmitt; Ralf O Floca; Daniel Paech; Rami A El Shafie; Ulf Neuberger; Martin Bendszus; Markus A Möhlenbruch; Dominik F Vollherbst
Journal:  Clin Neuroradiol       Date:  2021-04-14       Impact factor: 3.649

Review 10.  Glue, Onyx, Squid or PHIL? Liquid Embolic Agents for the Embolization of Cerebral Arteriovenous Malformations and Dural Arteriovenous Fistulas.

Authors:  Dominik F Vollherbst; René Chapot; Martin Bendszus; Markus A Möhlenbruch
Journal:  Clin Neuroradiol       Date:  2021-07-29       Impact factor: 3.649

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.